I have a complicated relationship with biotech stocks. I love the science, the unmet medical needs, and the possibility that one successful medicine can change both patients’ lives and a company’s value. I am less fond of waking up to discover that a clinical trial missed its primary endpoint and half my investment has evaporated before I have located the coffee. That is the biotech bargain. Investors are invited to study molecular targets, trial designs, competitive landscapes, safety profiles, and regulatory pathways. Then a press release arrives at 7:00 a.m. and reduces years of careful analysis to one merciless word: met or missed. This is why ACADIA Pharmaceuticals catches my attention. ACADIA, which trades under the ticker ACAD, does not fit neatly into the familiar small-biotech stereotype. It is not a pre-revenue company living from financing round to financing round while asking shareholders to remain patient for another eighteen months. It already sells two FDA-approved medic...